CD274 and non-small cell lung carcinoma: For example, Smit and colleagues found that 89Zr-durvalumab (anti PD-L1 antibody) tumour uptake was higher in patients with advanced NSCLC who had a response to durvalumab treatment, but did not correlate with tumour PD-L1 immunohistochemistry18.